Analysts Expect Pieris Pharmaceuticals Inc (PIRS) Will Post Quarterly Sales of $6.69 Million

Brokerages expect Pieris Pharmaceuticals Inc (NASDAQ:PIRS) to announce $6.69 million in sales for the current fiscal quarter, Zacks Investment Research reports. Four analysts have made estimates for Pieris Pharmaceuticals’ earnings. The lowest sales estimate is $4.50 million and the highest is $8.80 million. Pieris Pharmaceuticals reported sales of $18.15 million in the same quarter last year, which indicates a negative year-over-year growth rate of 63.1%. The business is scheduled to issue its next earnings results on Friday, March 8th.

On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.66 million for the current fiscal year, with estimates ranging from $28.70 million to $33.00 million. For the next fiscal year, analysts expect that the company will report sales of $22.74 million, with estimates ranging from $12.00 million to $31.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Pieris Pharmaceuticals.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its earnings results on Wednesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.15) by $0.04. Pieris Pharmaceuticals had a negative net margin of 17.90% and a negative return on equity of 18.07%. The company had revenue of $8.35 million for the quarter, compared to analyst estimates of $6.16 million.

PIRS has been the topic of a number of research reports. HC Wainwright set a $12.00 target price on shares of Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, September 4th. Cowen reiterated a “buy” rating on shares of Pieris Pharmaceuticals in a research report on Sunday, November 11th. BidaskClub raised shares of Pieris Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, October 16th. Finally, ValuEngine downgraded shares of Pieris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 10th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. Pieris Pharmaceuticals presently has an average rating of “Buy” and an average price target of $10.00.

In other Pieris Pharmaceuticals news, Director Christopher P. Kiritsy purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 14th. The stock was acquired at an average cost of $5.11 per share, with a total value of $25,550.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at approximately $51,100. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 5.07% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Public Employees Retirement System of Ohio bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $110,000. Marshall Wace LLP bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $118,000. Bowling Portfolio Management LLC bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $156,000. California Public Employees Retirement System bought a new stake in Pieris Pharmaceuticals in the second quarter valued at approximately $179,000. Finally, DRW Securities LLC increased its stake in Pieris Pharmaceuticals by 50.0% in the second quarter. DRW Securities LLC now owns 45,000 shares of the biotechnology company’s stock valued at $228,000 after purchasing an additional 15,000 shares in the last quarter. 65.36% of the stock is owned by institutional investors and hedge funds.

Shares of PIRS stock remained flat at $$3.51 during trading hours on Wednesday. 428,334 shares of the stock were exchanged, compared to its average volume of 569,235. Pieris Pharmaceuticals has a 12 month low of $3.04 and a 12 month high of $9.75. The firm has a market capitalization of $190.07 million, a price-to-earnings ratio of -8.78 and a beta of 1.88.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. It develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

See Also: What is a Futures Contract?

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply